CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anterogen Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anterogen Co Ltd
345-30 Gasan-dong, Geumcheon-gu
Phone: +82 221040391p:+82 221040391 SEOUL, 08589  South Korea Ticker: 065660065660
Business Summary
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohn’s fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Vice President, Director Mi HyeongKim 53 3/16/2022
Co-Chief Executive Officer, Director Seong GuLee 68 3/16/2022
Managing Director Bang HuiHan 55
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 37 (As of 12/31/2023)
Outstanding Shares: 9,731,373 (As of 12/31/2023)
Shareholders: 17,636
Stock Exchange: KDQ
Fax Number: +82 221040393


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024